Jarvelle
Show is providing you with access to breaking news that
is organized within caribbean countries, regional and U.S.
States specialized topic sections. Jarvelleshow 'News' page
content is derived from different online sources.
Note: Links
opens a new browser window.
Haiti
• http://metropolehaiti.com/metropole/frameset.html
• http://www.haitipressnetwork.com/
Other Caribbean News
• http://www.stabroeknews.com/
• http://www.jamaicaobserver.com/
• http://www.jamaica-gleaner.com/
• http://www.trinidadexpress.com/
• http://www.guardian.co.tt/
• http://www.newsday.co.tt
• http://www.nationnews.com/
The rest of the World
• http://www.wnafrica.com/
• http://www.wnaustralia.com/
• http://iafrica.com/news/sa/352885.htm
AIDS: Lab success is good news for
vaccine quest
Tue Nov 16 2004 10:02:15 ET
PARIS, Nov 16 (AFP) - French researchers announced on Tuesday
that, in laboratory conditions, they had stimulated antibodies
which dramatically barred the AIDS virus from infecting
human immune cells.
The results -- the first time such a success has ever been
achieved against such a wide genetic range of the virus
-- "open up interesting prospects for the development
of a vaccine against AIDS," the team said in a press
release.
"Twenty years after the human immunodeficiency virus
(HIV) was identified, the AIDS pandemic is one of the greatest
challenges to public health on a global scale.
"The need for a vaccine against HIV is thus greater
than ever."
Antibodies are the molecular frontline forces in the body's
defence system, designed to tag an invading virus or bacterium
so that it is destroyed by immune cells.
Many vaccines, such as those against the flu, polio and
measles, are based on antibodies, using a piece of the virus
to prime the immune system so that it identifies the intruder
in the future.
But antibody designs against HIV have so far been a huge
disappointment. So far, none has been found that can deliver
a big immune punch.
One suspected reason is that wild types of HIV may be somewhat
different from the strains used in labs.
Among wild strains, the proteins on the surface of the
virus which are often used as the antibody primers may be
more difficult to detect because they are folded over and
may be camouflaged by slippery sugar molecules.
Another likely reason for the failure is viral variety
-- with different sub-types of HIV and mutation, the antibodies
may be hunting an absent or a shifting target.
The French team has taken a different and more specific
tack, targeting a tiny area of a surface protein that, they
say confidently, is common across the range of HIV types.
This area is called CBD1 and is part of the gp41 protein.
CBD1 binds to a protein in the T-lymphocyte immune cell
called caveolin-1, thus helping the AIDS virus to dock to
and infiltrate its target.
The researchers synthesised a chain of peptides -- the
building blocks of proteins -- corresponding to CBD1 and
immunised rabbits with it.
In lab-dish experiments in which blood taken from the immunised
rabbits was exposed to human T-cells and the virus, it proved
to be a remarkable shield against a range of sub-types of
HIV-1, the commoner and more vicious form of the two big
strains of the virus.
"The anti-CBD1 antibodies work in two ways,"
the press statement said. "Firstly, they inhibit cellular
infection by HIV, and secondly, among cells that are already
infected, they lead to the production of defective viruses
(which) are unable to infect other cells."
The vaccine is only experimental and has not been applied
to any human volunteers to see whether it is safe or effective.
Even so, the findings are deeply encouraging, the French
scientists say.
"It shows that the CBD1 area can be used as a specific
target for developing an effective immune response."
The study, lead-authored by Ara Hovanessian of the Pasteur
Institute and National Centre for Scientific Research (CNRS),
was published on Tuesday in a specialist journal, Immunity.
More than 20 million people have died of AIDS and some
38 million more have HIV, the virus which causes it.
But in the entire 23-year history of AIDS, only one vaccine,
a design based on the gp120 protein, has ever gone through
the entire three-phase test process, and it proved a disappointing
flop.
|